Quality of life in patients with non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: a systematic review and meta-analysis

被引：0
|
作者：
Wei Liu
Qian Zhang
Tiantian Zhang
Li Li
Chunhua Xu
机构：
[1] Affiliated Nanjing Brain Hospital,Department of Respiratory Medicine
[2] Nanjing Medical University,undefined
[3] Clinical Center of Nanjing Respiratory Diseases and Imaging,undefined
来源：
World Journal of Surgical Oncology | / 20卷
关键词：
PD-1/PD-L1 inhibitors; Chemotherapy; Quality of life; Non-small cell lung cancer; Meta-analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Quality of life in patients with non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: a systematic review and meta-analysis
    Liu, Wei
    Zhang, Qian
    Zhang, Tiantian
    Li, Li
    Xu, Chunhua
    [J]. WORLD JOURNAL OF SURGICAL ONCOLOGY, 2022, 20 (01)
  • [2] Incidence of pneumonitis with use of PD-1 and PD-L1 inhibitors in non-small cell lung cancer: A systematic review and meta-analysis of trials
    Khunger, Monica
    Pasupuleti, Vinay
    Rakshit, Sagar
    Jain, Prantesh
    Mazzone, Peter J.
    Stevenson, James
    Pennell, Nathan A.
    Hernandez, Adrian V.
    Velcheti, Vamsidhar
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] Benefits and risks of PD-1/PD-L1 inhibitors for recurrent small cell lung cancer: A systematic review and meta-analysis
    Zhou, Juyue
    Du, Zhonghai
    Liang, Yan
    Zhang, Sensen
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2024, 193
  • [4] Incidence risk of PD-1/PD-L1 related diarrhea in non-small cell lung cancer (NSCLC) patients: a systematic review and meta-analysis
    Zhang, Caiqing
    Zhang, Shuisheng
    Xu, Deguo
    Liu, Rujun
    Zhu, Qingshan
    Zhao, Yi
    Mao, Yantao
    Tian, Yuan
    [J]. CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 3957 - 3969
  • [5] Soluble PD-L1 changes in advanced non-small cell lung cancer patients treated with PD-1 inhibitors: an individual patient data meta-analysis
    Shimizu, Takashi
    Inoue, Eisuke
    Ohkuma, Ryotaro
    Kobayashi, Shinichi
    Tsunoda, Takuya
    Wada, Satoshi
    [J]. FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [6] Efficacy of PD-1/PD-L1 inhibitors in patients with advanced non-small cell lung cancer: A meta-analysis of randomized clinical trials
    Peng, Tzu-Rong
    Wu, Ta-Wei
    [J]. THORACIC CANCER, 2019, 10 (05) : 1176 - 1181
  • [7] The safety of first and subsequent lines of PD-1/PD-L1 inhibitors monotherapy in non-small cell lung cancer patients: a meta-analysis
    Yang, Yilin
    Pang, Peilin
    Xie, Zihong
    Wang, Nian
    Liang, Hengrui
    Zhao, Lei
    [J]. TRANSLATIONAL CANCER RESEARCH, 2020, 9 (05) : 3231 - +
  • [8] Cardiovascular Toxicity With PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis
    Liu, Surui
    Gao, Wei
    Ning, Yan
    Zou, Xiaomeng
    Zhang, Weike
    Zeng, Liangjie
    Liu, Jie
    [J]. FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [9] Plasma Proteomic Analysis in Non-Small Cell Lung Cancer Patients Treated with PD-1/PD-L1 Blockade
    Eltahir, Mohamed
    Isaksson, Johan
    Mattsson, Johanna Sofia Margareta
    Karre, Klas
    Botling, Johan
    Lord, Martin
    Mangsbo, Sara M.
    Micke, Patrick
    [J]. CANCERS, 2021, 13 (13)
  • [10] Predictive effect of PD-L1 expression for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatment for non-small cell lung cancer: A meta-analysis
    Zhang, Binbin
    Liu, Yi
    Zhou, Sijing
    Jiang, Huihui
    Zhu, Ke
    Wang, Ran
    [J]. INTERNATIONAL IMMUNOPHARMACOLOGY, 2020, 80
12345